Fidelity Investments
BCLI

Fidelity Investments’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Fidelity Investments’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6
Closed -$7 – 5384
2025
Q2 		$7 Sell
6
-227
-97% -$254 ﹤0.01% 5297
2025
Q1 		$294 Buy
233
+122
+110% +$216 ﹤0.01% 5060
2024
Q4 		$252 Buy
+111
New +$205 ﹤0.01% 5042
2024
Q1 		– Sell
-8
Closed -$35 – 5366
2023
Q4 		$35 Buy
+8
New +$24 ﹤0.01% 5085
2023
Q2 		– Sell
-27
Closed -$1.32K – 5380
2023
Q1 		$1.32K Buy
+27
New +$783 ﹤0.01% 4704
2022
Q4 		– Sell
-2
Closed – – 5352
2022
Q3 		$0 Hold
2
– – ﹤0.01% 4849
2022
Q2 		$0 Buy
+2
New +$90 ﹤0.01% 4912
2021
Q4 		– Sell
-44
Closed -$2K – 4329
2021
Q3 		$2K Buy
+44
New +$2.31K ﹤0.01% 3979
2021
Q1 		– Sell
-47
Closed -$3K – 3973
2020
Q4 		$3K Hold
47
– – ﹤0.01% 3510
2020
Q3 		$12K Sell
47
-28
-37% -$5.73K ﹤0.01% 3150
2020
Q2 		$13K Sell
75
-16
-18% -$1.73K ﹤0.01% 3068
2020
Q1 		$6K Sell
91
-4
-4% -$312 ﹤0.01% 3209
2019
Q4 		$6K Sell
95
-89
-48% -$5.16K ﹤0.01% 3357
2019
Q3 		$11K Buy
+184
New +$10.9K ﹤0.01% 3203

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Fidelity Investments's BCLI Position: Q3 2025 in Review

Fidelity Investments sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 6 shares — an estimated $7 sold.

Fidelity Investments first reported a position in BCLI in Q3 2019 and held it in 14 quarters. The position peaked at $13K in Q2 2020. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • Fidelity Investments reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • Fidelity Investments sold 6 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $7.
  • Fidelity Investments first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2019 and held it in 14 quarters.
  • Fidelity Investments's BRAINSTORM CELL THERAPUTC position peaked at $13K in Q2 2020.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Fidelity Investments's 13F filing for Q3 2025, filed 13 Nov 2025.